A Phase 1 Study of E7080 in Subjects With Solid Tumor
Latest Information Update: 14 Nov 2018
Price :
$35 *
At a glance
- Drugs Lenvatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 31 May 2017 Results (n= 452) assessing optimal lenvatinib dose based on population PK and exposure-response analysis using using pooled data from NCT00946153, NCT00121719, NCT00121680, NCT00280397, NCT01268293 and other 8 phase 1 studies in healthy adults, published in the Journal of Clinical Pharmacology
- 20 May 2016 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information; JapicCTI111382 )
- 13 Feb 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.